Condition (MeSH)
Adenocarcinoma of Lung
ClinicalTrials.gov lists 420 trials for Adenocarcinoma of Lung or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 28.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
2 more sections with rows
402 of the 420 trials are tagged with Adenocarcinoma of Lung itself; the rest are tagged with a narrower condition beneath it.
When did Adenocarcinoma of Lung trials start? (33)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 22
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 15 |
| 2025 | 11 |
| 2024 | 16 |
| 2023 | 22 |
| 2022 | 22 |
| 2021 | 15 |
| 2020 | 22 |
| 2019 | 19 |
| 2018 | 13 |
| 2017 | 13 |
Showing 10 of 33 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 19 trials starting in 2026 and about 15 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 28 trials still running at the 2026-10-09 snapshot; registered median of 42 months across 250 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Adenocarcinoma of Lung trials in? (10)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 56 |
| Phase 1/2 | 31 |
| Phase 2 | 167 |
| Phase 2/3 | 4 |
| Phase 3 | 39 |
| Phase 4 | 2 |
| Not applicable | 26 |
| Observational | 92 |
| Expanded access | 2 |
| Unknown | 1 |
How many Adenocarcinoma of Lung trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 16 |
| Recruiting | 48 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 21 |
| Completed | 193 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Adenocarcinoma of Lung trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 28 |
| SWOG Cancer Research Network | 17 |
| Novartis Pharmaceuticals | 15 |
| Radiation Therapy Oncology Group | 9 |
| ECOG-ACRIN Cancer Research Group | 5 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Adenocarcinoma of Lung? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (nab)-paclitaxel | 49 |
| GEFITINIB | 18 |
| PEMBROLIZUMAB | 13 |
| CETUXIMAB | 10 |
| NIVOLUMAB | 9 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 65 |
| Radiation Therapy | 42 |
| Cisplatin 1 | 33 |
| Bevacizumab 1 | 32 |
| Gemcitabine/Gemzar | 26 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Adenocarcinoma of Lung trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutrophil count decreased | 620 | 16 |
| Fatigue | 447 | 34 |
| Hypertension | 337 | 20 |
| Neutropenia | 329 | 9 |
| White blood cell decreased | 295 | 9 |
Showing 5 of 10 adverse events.
Which publications cover Adenocarcinoma of Lung? (209)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma. | Nature cancer | 2025 | Yes |
| Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. | Nature medicine | 2025 | Yes |
| Multimodal radiopathological integration for prognosis and prediction of adjuvant chemotherapy benefit in resectable lung adenocarcinoma: A multicentre study. | Cancer letters | 2025 | Yes |
| Interplay of Polygenic Risk Score, Smoking Statuses, and Air Pollution on Lung Adenocarcinoma Risk in a Taiwanese Population. | Respirology (Carlton, Vic.) | 2025 | Yes |
| Evaluation of locoregional invasiveness of early lung adenocarcinoma manifesting as ground-glass nodules via [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT imaging. | European journal of nuclear medicine and molecular imaging | 2025 | Yes |
Showing 5 of 209 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.